Semaglutide and pancreatic cancer: a study denies the higher risk

The research fits into a panorama in which some studies had hypothesized a greater risk of pancreatic cancer for patients who use semaglutide. Further investigations were therefore requested. The Danish study used the national registers of Denmark, Sweden and Norway, sampling approximately 100,000 patients being treated for type 2 diabetes. The data collected showed that the risk of pancreatic cancer in these patients was the same as that of those taking anti-diabetic drugs belonging to other categories.

“This in-depth study, based on data from national registries in three countries, found no increased risk of pancreatic cancer associated with the use of semaglutide compared to other glucose-lowering drugs used in a similar therapeutic phase for the treatment of type 2 diabetes,” study coordinator Anton Pottegård said in a statement: “This evidence is also in line with currently available external data and further strengthens the evidence that semaglutide does not increase the risk of pancreatic cancer.”